Longitudinal assessment of systemic steroid therapy on hyperinflammatory endothelial biomarker profiles and serology responses of COVID-19 patients
J Transl Med
.
2022 Sep 8;20(1):411.
doi: 10.1186/s12967-022-03583-5.
Authors
Jonathan T Sims
1
,
Ching-Yun Chang
1
,
Josh Poorbaugh
1
,
Montanea Daniels
1
,
Stephanie L Beasley
1
,
Lin Zhang
1
,
George H Rodgers
1
,
Fabio Lena
2
,
Leonardo G Lacerenza
2
,
Bruno Sposato
2
,
Annabelle Dupont
3
,
Sophie Susen
3
,
Giacomo Casalini
4
,
Mario Corbellino
5
,
Justin Stebbing
6
,
Venkatesh Krishnan
7
Affiliations
1
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
2
Department of Pharmaceutical Medicine, Misericordia Hospital, Grosseto, Italy.
3
Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, University of Lille, 59000, Lille, France.
4
Luigi Sacco Department of Clinical and Biomedical Sciences, University of Milan, Milan, Italy.
5
Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy.
6
Department of Surgery and Cancer, Imperial College, London, UK.
7
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA. krishnan_gary@lilly.com.
PMID:
36076201
PMCID:
PMC9458306
DOI:
10.1186/s12967-022-03583-5
No abstract available
Keywords:
COVID-19; CXCL9; Cytokine; Dexamethasone; Inflammation; Serology.
Publication types
Letter
Research Support, Non-U.S. Gov't
MeSH terms
Biomarkers
COVID-19 Drug Treatment*
Humans
SARS-CoV-2
Steroids / therapeutic use
Substances
Biomarkers
Steroids